Stock Events

Nautilus Biotechnology 

$2.87
9
-$0.09-3.04% Thursday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
326.07M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

29
OCT
Earnings
 

Earnings

29OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.19
-0.12
-0.06
0
Expected EPS
-0.165
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NAUT. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides genomics solutions, including sequencing technologies that compete in the broader biotech market for genetic analysis.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers long-read sequencing technologies, directly competing in the genomic analysis space.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the life sciences sector.
Thermo Fisher Scientific
TMO
Mkt Cap234.95B
Thermo Fisher Scientific offers a wide range of biotechnology products, including analytical instruments and reagents, competing in the research and diagnostics markets.
Bio-Rad Laboratories
BIO
Mkt Cap9.35B
Bio-Rad Laboratories provides a variety of instruments and reagents for the life science research and clinical diagnostics markets, making it a competitor in biotech supplies.
Guardant Health
GH
Mkt Cap3.15B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing in the precision medicine and genomics field.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the genomic medicine sector, particularly in gene editing.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing in the gene editing and therapy market.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine works on gene editing technologies, competing in the development of genomic medicines for various diseases.

Analyst Ratings

4.5$Average Price Target
The highest estimate is $6.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

About

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Show more...
CEO
Employees
164
Country
US
ISIN
US63909J1088

Listings

XNAS
US
NAUT